Drug Trial Radar · NCT05340621
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
May 11, 2022
Primary completion
Jan 29, 2025
Study completion Jan 29, 2025
Sponsor
- Lead sponsor
- OnKure, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
Conditions
- RAS Mutation
- NRAS Gene Mutation
- Melanoma
Interventions
OKI-179 + binimetinibDrug
Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously. Phase 2: Patients will be treated with the RP2D.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Incidence and severity of dose-limiting toxicities (DLTs)Time frame: First 28 days of treatment
- Phase 1b: Incidence and severity of adverse events (AEs)Time frame: Phase 1b study duration (approximately 1.5 years)
- Phase 1b: Change in clinical laboratory abnormalitiesTime frame: Baseline through 30 days after end of study treatment
- Phase 1b: Change in Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Phase 1b study duration (approximately 1.5 years)
- Phase 2: Objective response rate (ORR)Time frame: Phase 2 study duration (approximately 3 years)
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
CTCA Phoenix, part of City of Hope
Phoenix, Arizona
University of California, San Francisco
San Francisco, California
University of Florida Health Cancer Center
Gainesville, Florida
Emory University Winship Cancer Institute
Atlanta, Georgia
CTCA Atlanta, part of City of Hope
Newnan, Georgia
CTCA Chicago, part of City of Hope
Zion, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Memorial Sloan-Kettering Cancer Center
New York, New York
Sarah Cannon Research Institute
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Virginia Health System
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.